Image 9 : évaluation de l’expression de RhoB et de l’instabilité génétique dans les tumeurs humaines
Annexe 9 : représentation schématique de l’irradiateur UVB
VI- M : Analyse statistique :
Les Variables continues sont présentées sous forme de moyenne (déviation standard, SD) ou médiane [interquartile range – IQR] selon la distribution. Les comparaisons de pourcentages ont été réalisées à l’aide du test de Chi2 ou le test de Fisher exact comme nécessaire. Les comparaisons de moyennes/médianes entre les groupes ont été réalisées par le test du t de Student pour échantillons doubles, le test de Mann Whitney, l’analyse de variance ou le test de Kruskal-Wallis comme nécessaire. Toutes les hypothèses ont été confrontées à un risque alpha de première espèce minimal de 5%.
Références :
1. Cancers de la peau -‐ Cancers de la peau -‐ Les recommandations -‐ Soins -‐ Institut National Du Cancer [Internet]. [cité 2011 oct 28]. Available de: http://www.e-‐
cancer.fr/soins/recommandations/cancers-‐de-‐la-‐peau
2. Marks R. An overview of skin cancers. Incidence and causation. Cancer. 1995 janv 15;75(2 Suppl):607-‐12.
3. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 2002 avr;146 Suppl 61:1-‐6.
4. Madan V, Lear JT, Szeimies R-‐M. Non-‐melanoma skin cancer. Lancet. 2010 févr 20;375(9715):673-‐85.
5. Diffey BL, Langtry JAA. Skin cancer incidence and the ageing population. Br. J. Dermatol. 2005 sept;153(3):679-‐80.
6. Martin L, Bonerandi J-‐J. [Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions]. Ann Dermatol Venereol. 2009 sept;136 Suppl 5:S163-‐164.
7. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Euvard S, Stockfleth E, et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br. J. Dermatol. 2007 mai;156 Suppl 3:1-‐7.
8. Holme SA, Malinovszky K, Roberts DL. Changing trends in non-‐melanoma skin cancer in South Wales, 1988-‐98. Br. J. Dermatol. 2000 déc;143(6):1224-‐9.
9. de Rijke JM, Schouten LJ, Hillen HF, Kiemeney LA, Coebergh JW, van den Brandt PA. Cancer in the very elderly Dutch population. Cancer. 2000 sept 1;89(5):1121-‐33. 10. Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-‐ melanoma skin cancer in Schleswig-‐Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br. J. Dermatol. 2003 déc;149(6):1200-‐6.
11. Plesko I, Severi G, Obsitníková A, Boyle P. Trends in the incidence of non-‐ melanoma skin cancer in Slovakia, 1978-‐1995. Neoplasma. 2000;47(3):137-‐42. 12. Wassberg C, Thörn M, Johansson AM, Bergström R, Berne B, Ringborg U.
Increasing incidence rates of squamous cell carcinoma of the skin in Sweden. Acta Derm. Venereol. 2001 sept;81(4):268-‐72.
13. Hannuksela-‐Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol. 1999 juill;135(7):781-‐6.
14. Saladi RN, Persaud AN. The causes of skin cancer: a comprehensive review. Drugs Today. 2005 janv;41(1):37-‐53.
15. Orphanet: Xeroderma pigmentosum [Internet]. [cité 2011 oct 28]. Available de: http://www.orpha.net/consor/cgi-‐bin/OC_Exp.php?Lng=GB&Expert=910
16. O’Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. Journal of the American Academy of Dermatology. 2011
août;65(2):253-‐61.
17. Iftner A, Klug SJ, Garbe C, Blum A, Stancu A, Wilczynski SP, et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of
nonimmunosuppressed individuals identifies high-‐risk genital types as possible risk factors. Cancer Res. 2003 nov 1;63(21):7515-‐9.
in immunocompetent individuals. Arch Dermatol. 2003 juill;139(7):890-‐4. 19. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B, Biol. 2001 oct;63(1-‐3):8-‐18.
20. MacKie RM. Long-‐term health risk to the skin of ultraviolet radiation. Prog. Biophys. Mol. Biol. 2006 sept;92(1):92-‐6.
21. Gallagher RP, Lee TK. Adverse effects of ultraviolet radiation: a brief review. Prog. Biophys. Mol. Biol. 2006 sept;92(1):119-‐31.
22. Joel Hillhouse GC, Thompson JK, Jacobsen PB, Hillhouse J. Investigating the role of appearance-‐based factors in predicting sunbathing and tanning salon use. J Behav Med. 2009 déc;32(6):532-‐44.
23. Schulman JM, Fisher DE. Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol. 2009 mars;21(2):144-‐9.
24. Karagas MR, Stannard VA, Mott LA, Slattery MJ, Spencer SK, Weinstock MA. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J. Natl. Cancer Inst. 2002 févr 6;94(3):224-‐6.
25. Lourari S, Paul C, Meyer N. [Non-‐surgical treatment of skin carcinomas and their precursors.]. Presse Med [Internet]. 2011 mars 16 [cité 2011 avr 21]; Available de: http://www.ncbi.nlm.nih.gov/pubmed/21419589
26. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J. Am. Acad. Dermatol. 1992 juin;26(6):976-‐90.
27. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008 mai 17;371(9625):1695-‐709.
28. Khansur T, Kennedy A. Cisplatin and 5-‐fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991 avr 15;67(8):2030-‐2. 29. Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-‐fluorouracil, and
bleomycin. Cancer. 1990 oct 15;66(8):1692-‐6.
30. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-‐cell carcinoma: three meta-‐analyses of updated individual data. MACH-‐NC Collaborative Group. Meta-‐Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000 mars 18;355(9208):949-‐55.
31. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-‐01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-‐stage oropharynx carcinoma. J. Clin. Oncol. 2004 janv 1;22(1):69-‐76.
32. Hitt R, Irigoyen A, Cortes-‐Funes H, Grau JJ, García-‐Sáenz JA, Cruz-‐Hernandez JJ. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-‐line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann. Oncol. [Internet]. 2011 août 23 [cité 2012 févr 13]; Available de: http://www.ncbi.nlm.nih.gov/pubmed/21865152
33. Maubec E, Petrow P, Scheer-‐Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II Study of Cetuximab As First-‐Line Single-‐Drug Therapy in Patients With Unresectable
de santé [Internet]. [cité 2011 nov 25]. Available de: http://www.afssaps.fr/Dossiers-‐ thematiques/Securite-‐des-‐produits-‐cosmetiques/Produits-‐solaires/(offset)/4
36. Freiman A, Yu J, Loutfi A, Wang B. Impact of melanoma diagnosis on sun-‐
awareness and protection: efficacy of education campaigns in a high-‐risk population. J Cutan Med Surg. 2004 oct;8(5):303-‐9.
37. Meyer N, Pruvost-‐Balland C, Bourdon-‐Lanoy E, Maubec E, Avri M-‐F. Awareness, knowledge and attitudes towards sun protection among skin cancer-‐treated patients in France. J Eur Acad Dermatol Venereol. 2007 avr;21(4):520-‐5.
38. Thomas M, Rioual E, Adamski H, Roguedas A-‐M, Misery L, Michel M, et al. Physicians involved in the care of patients with high risk of skin cancer should be trained regarding sun protection measures: evidence from a cross sectional study.
Journal of the European Academy of Dermatology and Venereology. 2011 janv;25:19-‐23. 39. Smith BJ, Ferguson C, McKenzie J, Bauman A, Vita P. Impacts from repeated mass media campaigns to promote sun protection in Australia. Health Promot Int. 2002 mars;17(1):51-‐60.
40. Boggild AK, From L. Barriers to sun safety in a Canadian outpatient population. J Cutan Med Surg. 2003 août;7(4):292-‐9.
41. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br. J. Dermatol. 1986
déc;115(6):649-‐55.
42. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-‐oriented perspective. Arch Dermatol. 1991 juill;127(7):1029-‐31.
43. Freeman SE, Hacham H, Gange RW, Maytum DJ, Sutherland JC, Sutherland BM. Wavelength dependence of pyrimidine dimer formation in DNA of human skin irradiated in situ with ultraviolet light. Proc. Natl. Acad. Sci. U.S.A. 1989
juill;86(14):5605-‐9.
44. Hussein MR. Ultraviolet radiation and skin cancer: molecular mechanisms. J. Cutan. Pathol. 2005 mars;32(3):191-‐205.
45. Anderson RR, Parrish JA. The optics of human skin. J. Invest. Dermatol. 1981 juill;77(1):13-‐9.
46. Kanofsky JR, Sima P. Singlet oxygen production from the reactions of ozone with biological molecules. J. Biol. Chem. 1991 mai 15;266(14):9039-‐42.
47. Papadopoulo D, Averbeck D, Moustacchi E. Mutagenic effects photoinduced in mammalian cells in vitro by two monofunctional pyridopsoralens. Photochem. Photobiol. 1986 juill;44(1):31-‐9.
48. Averbeck D, Papadopoulo D, Quinto I. Mutagenic effects of psoralens in yeast and V79 Chinese hamster cells. Natl Cancer Inst Monogr. 1984 déc;66:127-‐36.
49. Ananthaswamy HN, Pierceall WE. Molecular mechanisms of ultraviolet radiation carcinogenesis. Photochem. Photobiol. 1990 déc;52(6):1119-‐36.
50. Matsumura Y, Ananthaswamy HN. Molecular mechanisms of photocarcinogenesis. Front. Biosci. 2002 avr 1;7:d765-‐783.
51. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol. Appl. Pharmacol. 2004 mars 15;195(3):298-‐308.
52. Snopov SA, de Gruijl FR, Roza L, van der Leun JC. Immunochemical study of DNA modifications in the nuclei of UV-‐damaged lymphocytes. Photochem. Photobiol. Sci. 2004 janv;3(1):85-‐90.
development. Front. Biosci. 2002 juin 1;7:d1525-‐1530.
54. de Gruijl FR, van Kranen HJ, Mullenders LH. UV-‐induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J. Photochem. Photobiol. B, Biol. 2001 oct;63(1-‐3):19-‐27.
55. Hussein MR, Haemel AK, Wood GS. p53-‐related pathways and the molecular pathogenesis of melanoma. Eur. J. Cancer Prev. 2003 avr;12(2):93-‐100.
56. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Investig. Dermatol. Symp. Proc. 1996 avr;1(2):136-‐42.
57. Berne B, Pontén J, Pontén F. Decreased p53 expression in chronically sun-‐ exposed human skin after topical photoprotection. Photodermatol Photoimmunol Photomed. 1998 déc;14(5-‐6):148-‐53.
58. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994 déc 22;372(6508):773-‐6. 59. Bito T, Ueda M, Ahmed NU, Nagano T, Ichihashi M. Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinoma in relation to p53 expression. J. Cutan. Pathol. 1995 oct;22(5):427-‐34.
60. Onodera H, Nakamura S, Sugai T. Cell proliferation and p53 protein expressions in cutaneous epithelial neoplasms. Am J Dermatopathol. 1996 déc;18(6):580-‐8.
61. Stanimirović A, Cupić H, Bosnjak B, Kruslin B, Belicza M. Expression of p53, bcl-‐2 and growth hormone receptor in actinic keratosis, hypertrophic type. Arch. Dermatol. Res. 2003 juill;295(3):102-‐8.
62. Stanimirović A, Cupić H, Bosnjak B, Tomas D, Balicević D, Kruslin B, et al. Expression of p53, bcl-‐2 and growth hormone receptor in atrophic type of actinic keratosis. J. Dermatol. Sci. 2004 févr;34(1):49-‐53.
63. Stanimirović A, Cupić H, Bosnjak B, Tomas D, Kruslin B, Belicza M. TP53, Bcl-‐2 and growth hormone receptor expression in cutaneous squamous cell carcinoma. Acta Dermatovenerol Croat. 2005;13(4):201-‐5.
64. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc. Natl. Acad. Sci. U.S.A. 1993 mai 1;90(9):4216-‐20.
65. Rees J. Genetic alterations in non-‐melanoma skin cancer. J. Invest. Dermatol. 1994 déc;103(6):747-‐50.
66. Berhane T, Halliday GM, Cooke B, Barnetson RSC. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br. J. Dermatol. 2002 mai;146(5):810-‐5.
67. Korabiowska M, Brinck U, Betke H, Droese M, Berger H. Growth arrest DNA damage gene expression in naevi. In Vivo. 1999 juin;13(3):247-‐50.
68. Hildesheim J, Bulavin DV, Anver MR, Alvord WG, Hollander MC, Vardanian L, et al. Gadd45a protects against UV irradiation-‐induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res. 2002 déc 15;62(24):7305-‐15. 69. Hussein MRA-‐E, Wood GS. Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn. 2002 mai;4(2):71-‐80.
topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 1991 août 15;88(16):6961-‐5.
73. Isoherranen K, Sauroja I, Jansen C, Punnonen K. UV irradiation induces downregulation of bcl-‐2 expression in vitro and in vivo. Arch. Dermatol. Res. 1999 avr;291(4):212-‐6.
74. Batinac T, Zamolo G, Coklo M, Hadzisejdic I, Stemberger C, Zauhar G. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma. Pathol. Res. Pract. 2006;202(8):599-‐607.
75. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-‐2 proto-‐oncogene and the
gastrointestinal epithelial tumor progression model. Am. J. Pathol. 1995 janv;146(1):20-‐ 6.
76. Rutberg SE, Lee EJ, Hansen LH, Glick AB, Yuspa SH. Identification of differentially expressed genes in chemically induced skin tumors. Mol. Carcinog. 1997 sept;20(1):88-‐ 98.
77. Iordanov MS, Choi RJ, Ryabinina OP, Dinh T-‐H, Bright RK, Magun BE. The UV (Ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the Ras-‐extracellular signal-‐regulated kinase signaling cascade from the activated epidermal growth factor receptor. Mol. Cell. Biol. 2002 août;22(15):5380-‐94.
78. Kreimer-‐Erlacher H, Seidl H, Bäck B, Kerl H, Wolf P. High mutation frequency at Ha-‐ras exons 1-‐4 in squamous cell carcinomas from PUVA-‐treated psoriasis patients. Photochem. Photobiol. 2001 août;74(2):323-‐30.
79. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol. 1995 juill;131(7):796-‐800.
80. Welsh MM, Karagas MR, Kuriger JK, Houseman A, Spencer SK, Perry AE, et al. Genetic determinants of UV-‐susceptibility in non-‐melanoma skin cancer. PLoS ONE. 2011;6(7):e20019.
81. Khan SG, Mohan RR, Katiyar SK, Wood GS, Bickers DR, Mukhtar H, et al. Mutations in ras oncogenes: rare events in ultraviolet B radiation-‐induced mouse skin
tumorigenesis. Mol. Carcinog. 1996 févr;15(2):96-‐103.
82. Pierceall WE, Kripke ML, Ananthaswamy HN. N-‐ras mutation in ultraviolet radiation-‐induced murine skin cancers. Cancer Res. 1992 juill 15;52(14):3946-‐51. 83. Boureux A, Vignal E, Faure S, Fort P., Boureux A VE. Evolution of the Rho family of ras-‐like GTPases in eukaryotes. Mol Biol Evol. 2007;24(1):203-‐16.
84. Bustelo XR, Sauzeau V, Berenjeno IM., Bustelo XR SV. GTP-‐binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 2007;29(4):356-‐ 70.
85. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 2005;21:247-‐69.
86. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta. 2009 déc;1796(2):91-‐8.
87. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995 sept 1;269(5228):1270-‐2.
88. Qiu RG, Abo A, McCormick F, Symons M. Cdc42 regulates anchorage-‐independent growth and is necessary for Ras transformation. Mol. Cell. Biol. 1997 juin;17(6):3449-‐58. 89. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature. 1995 mars 30;374(6521):457-‐9.
91. Cappello S, Attardo A, Wu X, Iwasato T, Itohara S, Wilsch-‐Bräuninger M, et al. The Rho-‐GTPase cdc42 regulates neural progenitor fate at the apical surface. Nat. Neurosci. 2006 sept;9(9):1099-‐107.
92. Sanz-‐Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008 oct
31;135(3):510-‐23.
93. Bousquet E, Mazières J, Privat M, Rizzati V, Casanova A, Ledoux A, et al. Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1. Cancer Res. 2009 août 1;69(15):6092-‐9.
94. Embade N, Valerón PF, Aznar S, López-‐Collazo E, Lacal JC. Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production. Mol. Biol. Cell. 2000 déc;11(12):4347-‐58.
95. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett. 2001 avr 10;165(1):1-‐10.
96. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer. 2002 sept 9;87(6):635-‐44.
97. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-‐Jones A, Mokbel K, et al. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin. Cancer Res. 2003 déc 15;9(17):6432-‐40.
98. Adnane J, Muro-‐Cacho C, Mathews L, Sebti SM, Muñoz-‐Antonia T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin. Cancer Res. 2002 juill;8(7):2225-‐32.
99. Mazieres J, Antonia T, Daste G, Muro-‐Cacho C, Berchery D, Tillement V, et al. Loss of RhoB expression in human lung cancer progression. Clin. Cancer Res. 2004 avr 15;10(8):2742-‐50.
100. Liu AX, Rane N, Liu JP, Prendergast GC. RhoB is dispensable for mouse
development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol. Cell. Biol. 2001 oct;21(20):6906-‐ 12.
101. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 2000 juin 16;275(24):17974-‐8.
102. Fritz G, Kaina B. Ras-‐related GTPase RhoB forces alkylation-‐induced apoptotic cell death. Biochem. Biophys. Res. Commun. 2000 févr 24;268(3):784-‐9.
103. Liu A x, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 2000 août;20(16):6105-‐13.
104. Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res. 1999 nov
1;59(21):5492-‐6.
105. Fritz G, Kaina B, Aktories K. The ras-‐related small GTP-‐binding protein RhoB is immediate-‐early inducible by DNA damaging treatments. J. Biol. Chem. 1995 oct
and p300 to the distal CCAAT box of the RhoB promoter. Biochem. Biophys. Res. Commun. 2011 juin 3;409(2):211-‐6.
108. Westmark CJ, Bartleson VB, Malter JS. RhoB mRNA is stabilized by HuR after UV light. Oncogene. 2005 janv 13;24(3):502-‐11.
109. Glorian V, Maillot G, Polès S, Iacovoni JS, Favre G, Vagner S. HuR-‐dependent loading of miRNA RISC to the mRNA encoding the Ras-‐related small GTPase RhoB controls its translation during UV-‐induced apoptosis. Cell Death Differ. 2011 nov;18(11):1692-‐701.
110. Canguilhem B, Pradines A, Baudouin C, Boby C, Lajoie-‐Mazenc I, Charveron M, et al. RhoB protects human keratinocytes from UVB-‐induced apoptosis through epidermal growth factor receptor signaling. J. Biol. Chem. 2005 déc 30;280(52):43257-‐63.
111. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 1988 mars;106(3):761-‐71.
112. Decraene D, Agostinis P, Pupe A, de Haes P, Garmyn M. Acute response of human skin to solar radiation: regulation and function of the p53 protein. J. Photochem.
Photobiol. B, Biol. 2001 oct;63(1-‐3):78-‐83.
113. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J. Invest.
Dermatol. 2003 janv;120(1):48-‐55.
114. Sharma MR, Werth B, Werth VP. Animal models of acute photodamage: comparisons of anatomic, cellular and molecular responses in C57BL/6J, SKH1 and Balb/c mice. Photochem. Photobiol. 2011 juin;87(3):690-‐8.
115. Benavides F, Oberyszyn TM, VanBuskirk AM, Reeve VE, Kusewitt DF. The hairless mouse in skin research. J. Dermatol. Sci. 2009 janv;53(1):10-‐8.
116. de Gruijl FR, Forbes PD. UV-‐induced skin cancer in a hairless mouse model. Bioessays. 1995 juill;17(7):651-‐60.
117. Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol. Cell. Biol. 2004 juin;24(12):5565-‐76.
118. Liu Ax, Cerniglia GJ, Bernhard EJ, Prendergast GC. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2001 mai 22;98(11):6192-‐7.
119. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-‐stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998 mars 6;273(10):5858-‐68.
120. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 2000 août 27;10(15):886-‐95.
121. Rogakou EP, Nieves-‐Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 2000 mars 31;275(13):9390-‐5.
122. Farasat S, Yu SS, Neel VA, Nehal KS, Lardaro T, Mihm MC, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J. Am. Acad. Dermatol. 2011 juin;64(6):1051-‐9.
123. Ibuki Y, Goto R. Suppression of apoptosis by UVB irradiation: survival signaling via PI3-‐kinase/Akt pathway. Biochem. Biophys. Res. Commun. 2000 déc 29;279(3):872-‐
124. Decraene D, Van Laethem A, Agostinis P, De Peuter L, Degreef H, Bouillon R, et al. AKT status controls susceptibility of malignant keratinocytes to the early-‐activated and UVB-‐induced apoptotic pathway. J. Invest. Dermatol. 2004 juill;123(1):207-‐12.
125. Claerhout S, Decraene D, Van Laethem A, Van Kelst S, Agostinis P, Garmyn M. AKT delays the early-‐activated apoptotic pathway in UVB-‐irradiated keratinocytes via BAD translocation. J. Invest. Dermatol. 2007 févr;127(2):429-‐38.
126. Pan J, She M, Xu Z-‐X, Sun L, Yeung S-‐CJ. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res. 2005 mai
1;65(9):3671-‐81.